Curi Bio

Curi Bio develops human-relevant platforms that integrate human cells, biological systems, and data to support the discovery of new medicines. The company focuses on human induced pluripotent stem cell (iPSC)-based products and services, enabling scientists to build mature and predictive iPSC-derived tissues with a primary focus on cardiac, musculoskeletal, and disease models. Through an integrated platform combining advanced 3D tissue models, biosystems for functional analysis, and AI/ML-enabled data insights, Curi Bio supports drug safety, efficacy, and potency assessments across the preclinical drug development process.

Curi Bio serves researchers and drug discovery teams seeking to improve the predictive accuracy of preclinical pipelines. The company offers a combination of physical biosystem platforms, cell and tissue models, data analytics software, and contract research services under its Curi Engine offering.

Biosystem Platforms

• Mantarray™ – a platform for 3D tissue contractility analysis, designed to measure the functional output of engineered muscle tissues.
• Mantarray Mini Plates – a variant of the Mantarray platform designed to generate more data while using fewer cells.
• Nautilai™ – a platform for voltage and calcium imaging, enabling electrophysiological and calcium transient measurements.
• Stingray™ – a system focused on the maturation of 3D engineered tissues.
• NanoSurface™ Plates – high-content imaging (HCI) plates designed to support structural maturation of cells.

Data Analytics Platforms

• Pulse™ – a high-throughput video contractility analysis software providing access to information-rich, human-relevant functional data from 2D and 3D tissue models.

Cell and Tissue Models

• Cardiac Models – iPSC-derived cardiomyocyte-based models for cardiac research and drug testing.
• Skeletal Muscle Models – both 2D and 3D engineered skeletal muscle tissue models for functional assessments.
• Neuromuscular Junction Model – a model system for studying the interface between motor neurons and muscle tissue.
• Disease Models – including a Duchenne Muscular Dystrophy (DMD) disease model; histological characterization shows DMD tissues lack dystrophin-positive myotubes.
• MYBPC3 HCM Cardiomyocytes – cardiomyocytes carrying the MYBPC3 mutation associated with hypertrophic cardiomyopathy.
• Celogics Celo.Cardiomyocytes – a cardiomyocyte product available through the Celogics line.

Cells and Media Products

• 3D Skeletal Muscle Tissue Media formulated for use with 3D skeletal muscle tissue models.
• Skeletal Muscle Myoblasts for use in model construction and research applications.
• 3D Cardiac Media for supporting 3D cardiac tissue culture and maturation.

Curi Engine™ Services

• Curi Bio offers contract research and partnership services under the Curi Engine brand, providing a workflow that spans the preclinical drug development process.
• The Curi Engine is focused on human disease models of contractile and excitable tissues, merging functional and analytical assessments to inform R&D decision-making.
• The service is available to organizations seeking to increase the predictive accuracy of their preclinical pipelines through partnership with Curi Bio.

Curi Bio also provides a range of scientific resources including publications, application notes, product literature, webinars, posters, videos, and a knowledge base, as well as a global distributor network and a workshop world tour program for customer engagement and education.